BMI View: Political instability and thus risk will remain elevated over the coming quarters in Brazil,
contributing to increasing uncertainty in terms of policy direction within the pharmaceuticals and
healthcare sector. Nonetheless, over a multiyear timeframe, the Br ..."
BMI View: Chile's healthcare reform and sector investment will continue to expand the role of the state in
the provision of health services and medicines. The stable political and economic outlook in Chile provides
a solid foundation for the government to launch assis ..."
BMI View: The Argentinean pharmaceutical market will continue to experience downward pressure owing
to a contraction in consumption indices in the near term. In the long term, however, market growth
fundamentals will remain robust, creating commercial and investment o ..."
BMI View: The presidential election result will maintain the attractiveness of Peru's pharmaceutical and
healthcare sector. A Fujimori administration will further bolster Peru's business environment and
encourage increasing investment in Peru's pharmaceutical manufact ..."
BMI View: Multinational pharmaceutical companies will increasingly experience the negative currency
impact of Venezuela's recent reforms which will allow for much more rapid currency depreciation for the
Simadi rate. It is our long-standing view that currency devaluat ..."
BMI View: Colombia's deteriorating regulatory regime will continue to limit the country's attractiveness to
multinational pharmaceutical companies in the coming years. Despite the country's growing rates of
medicine consumption, the increasing compulsory license risks ..."
BMI View: Chile's government will continue to increase its investment in healthcare and play an
increasingly important role in providing greater healthcare coverage to local citizens. This will offer
considerable commercial opportunities for pharmaceutical companies a ..."
BMI View: Chinese investment in Ecuador's pharmaceutical and healthcare sector will continue to be
pertinent for the country in order for it to meet the increasing demand of medicines within its public
healthcare sector. Foreign generic drugmakers will, however, face ..."
BMI View: In the near term, the substandard regulatory and market access environment will continue to
tarnish Argentina's appeal to drugmakers. However, in the long term, Argentina stands among the most
promising pharmaceutical markets in Latin America in terms of gro ..."
BMI View: The current state of political uncertainty will not shake Brazil's leading position as Latin
America's largest pharmaceutical and healthcare market. The Brazilian government has been committed to
improving the population's access to healthcare for decades. H ..."